Feb 09, 2021
Lannett Expands Strategic Relationship To Include Biosimilar Fast-Acting Insulin
Feb 03, 2021
Lannett Announces Fiscal 2021 Second-Quarter Financial Results In Line Or Above Expectations
Nov 30, 2020
Lannett Pays Off, In Full, Remaining Term A Loans
Nov 04, 2020
Lannett Announces Fiscal 2021 First-quarter Financial Results; Affirms Guidance
Nov 03, 2020
Lannett Launches Authorized Generic of Tirosint® (Levothyroxine Sodium Capsules)
Aug 26, 2020
Lannett Announces Fiscal 2020 Fourth-Quarter, Full-Year Financial Results
Aug 19, 2020
Lannett To Report Fiscal 2020 Fourth-Quarter, Full-Year Financial Results, Host Conference Call On Wednesday, August 26
Aug 17, 2020
Lannett Announces Notice Of Proposed Settlement And Dismissal With Prejudice Of Derivative Action
Aug 17, 2020
Lannett Signs Agreement To Be Exclusive Distributor Of Generic Flovent® Diskus®
Aug 03, 2020
Lannett Announces Launch Of FDA Approved Levothyroxine Tablets
Jul 27, 2020
Lannett To Launch Levorphanol Tablets
Jul 23, 2020
Lannett Launches Mexiletine HCl Capsules
Jul 16, 2020
Lannett And Cediprof Announce Exclusive Distribution Agreement For An Approved Levothyroxine
Jul 13, 2020
Lannett Announces Restructuring, Cost Reduction Initiatives
Jun 11, 2020
Lannett Provides Update On Clinical Advancement Of Biosimilar Insulin Glargine, Following FDA Meeting
May 06, 2020
Lannett Announces Fiscal 2020 Third-Quarter Financial Results
Apr 29, 2020
Lannett To Report Fiscal 2020 Third-Quarter Financial Results, Host Conference Call On Wednesday, May 6
Apr 08, 2020
Lannett To Meet With FDA Regarding The Clinical Advancement Of Biosimilar Insulin Glargine On June 9
Mar 31, 2020
Lannett Begins Marketing Generic Adderall® XR
Feb 05, 2020
Lannett Announces Fiscal 2020 Second-Quarter Financial Results